First Time Loading...

Bristol-Myers Squibb Co
NYSE:BMY

Watchlist Manager
Bristol-Myers Squibb Co Logo
Bristol-Myers Squibb Co
NYSE:BMY
Watchlist
Price: 48.79 USD -0.41% Market Closed
Updated: Apr 24, 2024

Intrinsic Value

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. [ Read More ]

The intrinsic value of one BMY stock under the Base Case scenario is 74.86 USD. Compared to the current market price of 48.79 USD, Bristol-Myers Squibb Co is Undervalued by 35%.

Key Points:
BMY Intrinsic Value
Base Case
74.86 USD
Undervaluation 35%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Bristol-Myers Squibb Co

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling BMY stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Bristol-Myers Squibb Co

Provide an overview of the primary business activities
of Bristol-Myers Squibb Co.

What unique competitive advantages
does Bristol-Myers Squibb Co hold over its rivals?

What risks and challenges
does Bristol-Myers Squibb Co face in the near future?

Has there been any significant insider trading activity
in Bristol-Myers Squibb Co recently?

Summarize the latest earnings call
of Bristol-Myers Squibb Co.

What significant events have occurred
in Bristol-Myers Squibb Co over the past months?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Bristol-Myers Squibb Co.

Provide P/S
for Bristol-Myers Squibb Co.

Provide P/E
for Bristol-Myers Squibb Co.

Provide P/OCF
for Bristol-Myers Squibb Co.

Provide P/FCFE
for Bristol-Myers Squibb Co.

Provide P/B
for Bristol-Myers Squibb Co.

Provide EV/S
for Bristol-Myers Squibb Co.

Provide EV/GP
for Bristol-Myers Squibb Co.

Provide EV/EBITDA
for Bristol-Myers Squibb Co.

Provide EV/EBIT
for Bristol-Myers Squibb Co.

Provide EV/OCF
for Bristol-Myers Squibb Co.

Provide EV/FCFF
for Bristol-Myers Squibb Co.

Provide EV/IC
for Bristol-Myers Squibb Co.

Show me price targets
for Bristol-Myers Squibb Co made by professional analysts.

What are the Revenue projections
for Bristol-Myers Squibb Co?

How accurate were the past Revenue estimates
for Bristol-Myers Squibb Co?

What are the Net Income projections
for Bristol-Myers Squibb Co?

How accurate were the past Net Income estimates
for Bristol-Myers Squibb Co?

What are the EPS projections
for Bristol-Myers Squibb Co?

How accurate were the past EPS estimates
for Bristol-Myers Squibb Co?

What are the EBIT projections
for Bristol-Myers Squibb Co?

How accurate were the past EBIT estimates
for Bristol-Myers Squibb Co?

Compare the revenue forecasts
for Bristol-Myers Squibb Co with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Bristol-Myers Squibb Co and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Bristol-Myers Squibb Co against its competitors.

Analyze the profit margins
(gross, operating, and net) of Bristol-Myers Squibb Co compared to its peers.

Compare the P/E ratios
of Bristol-Myers Squibb Co against its peers.

Discuss the investment returns and shareholder value creation
comparing Bristol-Myers Squibb Co with its peers.

Analyze the financial leverage
of Bristol-Myers Squibb Co compared to its main competitors.

Show all profitability ratios
for Bristol-Myers Squibb Co.

Provide ROE
for Bristol-Myers Squibb Co.

Provide ROA
for Bristol-Myers Squibb Co.

Provide ROIC
for Bristol-Myers Squibb Co.

Provide ROCE
for Bristol-Myers Squibb Co.

Provide Gross Margin
for Bristol-Myers Squibb Co.

Provide Operating Margin
for Bristol-Myers Squibb Co.

Provide Net Margin
for Bristol-Myers Squibb Co.

Provide FCF Margin
for Bristol-Myers Squibb Co.

Show all solvency ratios
for Bristol-Myers Squibb Co.

Provide D/E Ratio
for Bristol-Myers Squibb Co.

Provide D/A Ratio
for Bristol-Myers Squibb Co.

Provide Interest Coverage Ratio
for Bristol-Myers Squibb Co.

Provide Altman Z-Score Ratio
for Bristol-Myers Squibb Co.

Provide Quick Ratio
for Bristol-Myers Squibb Co.

Provide Current Ratio
for Bristol-Myers Squibb Co.

Provide Cash Ratio
for Bristol-Myers Squibb Co.

What is the historical Revenue growth
over the last 5 years for Bristol-Myers Squibb Co?

What is the historical Net Income growth
over the last 5 years for Bristol-Myers Squibb Co?

What is the current Free Cash Flow
of Bristol-Myers Squibb Co?

Discuss the annual earnings per share (EPS)
trend over the past five years for Bristol-Myers Squibb Co.

Financials

Balance Sheet Decomposition
Bristol-Myers Squibb Co

Current Assets 31.8B
Cash & Short-Term Investments 12.3B
Receivables 15.3B
Other Current Assets 4.2B
Non-Current Assets 63.4B
Long-Term Investments 2.1B
PP&E 8B
Intangibles 48.2B
Other Non-Current Assets 5B
Current Liabilities 22.3B
Accounts Payable 3.3B
Accrued Liabilities 11.2B
Short-Term Debt 246m
Other Current Liabilities 7.6B
Non-Current Liabilities 43.5B
Long-Term Debt 36.7B
Other Non-Current Liabilities 6.8B
Efficiency

Earnings Waterfall
Bristol-Myers Squibb Co

Revenue
45B USD
Cost of Revenue
-10.6B USD
Gross Profit
34.4B USD
Operating Expenses
-23.6B USD
Operating Income
10.8B USD
Other Expenses
-2.8B USD
Net Income
8B USD

Free Cash Flow Analysis
Bristol-Myers Squibb Co

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
Fundamental Scores

BMY Profitability Score
Profitability Due Diligence

Bristol-Myers Squibb Co's profitability score is 63/100. The higher the profitability score, the more profitable the company is.

63/100
Profitability
Score

Bristol-Myers Squibb Co's profitability score is 63/100. The higher the profitability score, the more profitable the company is.

BMY Solvency Score
Solvency Due Diligence

Bristol-Myers Squibb Co's solvency score is 46/100. The higher the solvency score, the more solvent the company is.

Long-Term Solvency
Short-Term Solvency
Average D/E
Average Altman Z-Score
46/100
Solvency
Score

Bristol-Myers Squibb Co's solvency score is 46/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

BMY Price Targets Summary
Bristol-Myers Squibb Co

Wall Street analysts forecast BMY stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for BMY is 57.07 USD with a low forecast of 40.4 USD and a high forecast of 78.75 USD.

Lowest
Price Target
40.4 USD
17% Downside
Average
Price Target
57.07 USD
17% Upside
Highest
Price Target
78.75 USD
61% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

BMY Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

BMY Price
Bristol-Myers Squibb Co

1M 1M
-7%
6M 6M
-13%
1Y 1Y
-31%
3Y 3Y
-21%
5Y 5Y
+24%
10Y 10Y
+25%
Annual Price Range
48.79
52w Low
47.84
52w High
70.54
Price Metrics
Average Annual Return 17.37%
Standard Deviation of Annual Returns 20.75%
Max Drawdown -40%
Shares Statistics
Market Capitalization 98.6B USD
Shares Outstanding 2 033 000 000
Percentage of Shares Shorted 1.73%

BMY Return Decomposition
Main factors of price return

What is price return decomposition?

BMY News

Other Videos

Last Important Events
Bristol-Myers Squibb Co

Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.

All
Positive
Negative

Sentiment Analysis
Bristol-Myers Squibb Co

Today
Last 7 Days 7D
Last 30 Days 30D
Last 90 Days 90D

Company Profile

Bristol-Myers Squibb Co Logo
Bristol-Myers Squibb Co

Country

United States of America

Industry

Pharmaceuticals

Market Cap

98.6B USD

Dividend Yield

4.9%

Description

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. The company is headquartered in New York City, New York and currently employs 32,200 full-time employees. The firm is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The firm offers products for a range of therapeutic classes, which include oncology, immunology, cardiovascular and fibrosis. The Company’s pharmaceutical products include chemically-synthesized or small molecule drugs and products produced from biological processes, called biologics. Small molecule drugs are administered orally in the form of a pill or tablet. Biologics are administered to patients through injections or by infusion. The Company’s products include Revlimid, Eliquis, Opdivo, Orencia, Pomalyst/Imnovid, Sprycel, Yervoy, Abraxane, Empliciti, Reblozyl, Inrebic, Onureg, Zeposia, Vidaza, Baraclude and Breyanzi. Its products are sold to wholesalers, distributors, pharmacies, retailers, hospitals, clinics and government agencies.

Contact

NEW YORK
New York City
430 E 29th St Fl 14
+12125464000.0
https://www.bms.com/

IPO

1929-07-05

Employees

32 200

Officers

Executive Chairman of the Board
Dr. Giovanni Caforio M.D.
CEO & Director
Dr. Christopher S. Boerner Ph.D.
Executive VP & CFO
Mr. David V. Elkins
Executive VP & General Counsel
Ms. Sandra Leung Esq.
Executive VP and Chief Digital & Technology Officer
Mr. Greg Meyers
VP & Head of Investor Relations
Mr. Timothy Power
Show More
Chief Compliance & Ethics Officer
Ms. Kimberly M. Jablonski
Executive Vice President & Chief Human Resources Officer
Ms. Ahn Amanda Poole
Executive VP & Chief Medical Officer of Drug Development
Mr. Samit Hirawat M.D.
Head of Medical Affairs
Dr. Joseph J. Eiden Jr.
Show Less

See Also

Discover More
What is the Intrinsic Value of one BMY stock?

The intrinsic value of one BMY stock under the Base Case scenario is 74.86 USD.

Is BMY stock undervalued or overvalued?

Compared to the current market price of 48.79 USD, Bristol-Myers Squibb Co is Undervalued by 35%.